膵臓がん診断市場- 世界の産業規模、動向、機会、予測、検査タイプ別、がんタイプ別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

膵臓がん診断の世界市場規模は2024年に28億7,000万米ドル、2030年には43億2,000万米ドルに達すると予測され、予測期間中のCAGRは7.05％を記録します。

同市場は、膵臓がんの罹患率の増加、低侵襲診断技術に対する需要の増加、研究開発投資の増加により勢いを増しています。膵臓がんは、進行が静かで発見が遅いため、依然として最も致命的ながんの1つです。早期スクリーニングとその生存結果への影響に関する認識が高まるにつれ、効果的な診断ツールに対する需要が大幅に増加しています。さらに、世界人口の高齢化（特に60歳以上）が膵臓がんの罹患率上昇に寄与しており、早期発見技術と診断の進歩に対する需要をさらに押し上げています。

市場促進要因

膵臓がん罹患率の上昇

主な市場課題

非特異的症状による診断の遅れ

主要市場動向

早期発見と個別化医療の重視

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の膵臓がん診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 検査タイプ別（画像診断検査、生検、血液検査、肝機能検査、その他）
  • がんタイプ別（外分泌がん、腺がん、扁平上皮がん、膠芽腫、その他）
  • エンドユーザー別（病院・診療所、診断センター、その他）
  • 地域別
  • 企業別（2024）
• 製品マップ
  • 検査タイプ別
  • がんタイプ別
  • エンドユーザー別
  • 地域別

第6章 北米の膵臓がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の膵臓がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の膵臓がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の膵臓がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの膵臓がん診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界の膵臓がん診断市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Siemens Healthineers AG
• Myriad Genetics, Inc.
• Pfizer, Inc
• Novartis AG
• AstraZeneca plc
• Immunovia AB
• Laboratory Corporation of America Holdings
• Abbott Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Pancreatic Cancer Diagnostics Market was valued at USD 2.87 billion in 2024 and is projected to reach USD 4.32 billion by 2030, registering a CAGR of 7.05% during the forecast period. The market is gaining momentum due to the growing incidence of pancreatic cancer, increased demand for minimally invasive diagnostic techniques, and rising investments in R&D. Pancreatic cancer remains one of the deadliest forms of cancer due to its silent progression and late-stage detection. As awareness grows around early screening and its impact on survival outcomes, the demand for effective diagnostic tools has increased significantly. Moreover, the aging global population-particularly those aged 60 and above-has contributed to a higher incidence of pancreatic cancer, further driving demand for early detection technologies and diagnostic advancements.

Key Market Drivers

Rising Incidence of Pancreatic Cancer

The rising global incidence of pancreatic cancer serves as a major catalyst for the growth of the pancreatic cancer diagnostics market. According to the American Cancer Society, around 66,440 individuals in the U.S. are expected to be diagnosed with pancreatic cancer in 2024, with an estimated 51,750 fatalities. This high mortality rate emphasizes the urgency for improved diagnostic solutions. Globally, the increasing burden of pancreatic cancer is influenced by aging populations, evolving lifestyles, and environmental risk factors. As the disease is often diagnosed at a late stage due to its aggressive progression, healthcare systems are focusing more on developing advanced diagnostics that enable early and accurate detection.

Key Market Challenges

Late Diagnosis Due to Non-Specific Symptoms

One of the primary obstacles in pancreatic cancer diagnostics is the difficulty in early detection due to vague and non-specific symptoms such as abdominal discomfort, unexplained weight loss, and jaundice. These symptoms often resemble those of less severe conditions, causing significant delays in diagnosis. As a result, patients are frequently diagnosed at advanced stages when treatment options are limited. Although novel tools like the PAC-MANN blood test-showing 85% accuracy when used alongside CA 19-9-present promising results, broader implementation remains hindered by the need for further clinical validation and regulatory approvals.

Key Market Trends

Emphasis on Early Detection and Personalized Medicine

A prominent trend shaping the pancreatic cancer diagnostics market is the increasing emphasis on early detection and the integration of personalized medicine. Advances in diagnostic technologies, including experimental blood tests with up to 97% accuracy for stage 1 and 2 cancers, highlight the potential for improving outcomes through early diagnosis. Simultaneously, personalized approaches based on genetic profiling are gaining traction. Genomic testing enables identification of actionable mutations, allowing clinicians to customize treatment plans. Recent studies indicate that nearly one-third of patients with advanced pancreatic cancer had their treatments modified based on such insights, reinforcing the growing importance of precision diagnostics.

Key Market Players

• Siemens Healthineers AG
• Myriad Genetics, Inc.
• Pfizer, Inc
• Novartis AG
• AstraZeneca plc
• Immunovia AB
• Laboratory Corporation of America Holdings
• Abbott Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pancreatic Cancer Diagnostics Market, By Test Type:

• Diagnostic Imaging Tests
• Biopsy
• Blood Tests
• Liver Function Tests
• Others

Pancreatic Cancer Diagnostics Market, By Cancer Type:

• Exocrine
• Adenocarcinoma
• Squamous Cell Carcinoma
• Colloid Carcinoma
• Others

Pancreatic Cancer Diagnostics Market, By End User:

• Hospitals & Clinics
• Diagnostic Centers
• Others

Pancreatic Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Diagnostics Market.

Available Customizations:

Global Pancreatic Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pancreatic Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Diagnostic Imaging Tests, Biopsy, Blood Tests, Liver Function Tests, Others)
    • 5.2.1.1. By Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others)
  • 5.2.2. By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Map
  • 5.3.1. By Test Type
  • 5.3.2. By Cancer Type
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America Pancreatic Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Cancer Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pancreatic Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Cancer Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Pancreatic Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Cancer Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Pancreatic Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Cancer Type
      • 6.3.3.2.3. By End User

7. Europe Pancreatic Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Cancer Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Cancer Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Cancer Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Cancer Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Cancer Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Cancer Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Pancreatic Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Cancer Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Cancer Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Cancer Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Cancer Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Cancer Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Cancer Type
      • 8.3.5.2.3. By End User

9. South America Pancreatic Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Cancer Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pancreatic Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Cancer Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Pancreatic Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Cancer Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Pancreatic Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Cancer Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Pancreatic Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Cancer Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pancreatic Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Cancer Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Pancreatic Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Cancer Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Pancreatic Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Cancer Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Pancreatic Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Siemens Healthineers AG
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Myriad Genetics, Inc.
• 15.3. Pfizer, Inc
• 15.4. Novartis AG
• 15.5. AstraZeneca plc
• 15.6. Immunovia AB
• 15.7. Laboratory Corporation of America Holdings
• 15.8. Abbott Laboratories
• 15.9. Agilent Technologies, Inc.
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer